bioMérieux: targets 2023 sales growth of 4% to 6%
(CercleFinance.com) - bioMérieux's sales reached 3,589 million euros in 2022 compared to 3,376 million euros in 2021, with organic growth of 0.
2%: reported growth (in euros) was 6.3%.
For FY 2022, contributed current operating income was 664 million euros, i.e. 18.5% of sales, down 21% y-o-y. The company's 2022 gross profit reached 2,009 million euros, i.e. 56% of sales, down from 59.3% at end-December 2021.
The group's operating profit reached 587 million euros at the end of the year, down 25% y-o-y. Net income, group share reached 452 million euros (compared to 601 million euros in 2021).
In 2023, LFL sales growth, excluding respiratory panels, is expected between +8% and +10%. Total sales growth is expected between +4% and +6% in 2023.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
2%: reported growth (in euros) was 6.3%.
For FY 2022, contributed current operating income was 664 million euros, i.e. 18.5% of sales, down 21% y-o-y. The company's 2022 gross profit reached 2,009 million euros, i.e. 56% of sales, down from 59.3% at end-December 2021.
The group's operating profit reached 587 million euros at the end of the year, down 25% y-o-y. Net income, group share reached 452 million euros (compared to 601 million euros in 2021).
In 2023, LFL sales growth, excluding respiratory panels, is expected between +8% and +10%. Total sales growth is expected between +4% and +6% in 2023.
Copyright (c) 2023 CercleFinance.com. All rights reserved.